News Sun Pharma buys Checkpoint and its new cancer drug Sun Pharma has agreed to acquire Checkpoint Therapeutics, which recently claimed FDA approval for its first drug but is also running short on cash.
News FDA says no to Checkpoint’s skin cancer drug cosibelimab Checkpoint Therapeutics’ late entry into the PD-1/PD-L1 inhibitor category, cosibelimab, just got knocked back even further after it was turned down by the FDA as a treatm
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.